Biology of Blood and Marrow Transplantation This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Trajectory of Sleep, Depression, and Quality of Life in Pediatric HSCT Recipients
Adult hematopoietic stem cell transplant (HSCT) recipients and adult caregivers of pediatric HSCT recipients have poor sleep, due in part to nocturia, staff cares, and noise [1 –5]. In these patients, the effects of prolonged sleep disruption during hospitalization have been shown to persist for months after discharge, negatively affecting sleep hygiene as well as quality of life [6–8]. Adult HSCT patients have been shown to have sleep disturbances up to 1-year post-tr ansplant, and these disturbances occur concurrently with depression and anxiety [9,10]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 3, 2024 Category: Hematology Authors: YunZu Michele Wang, John F. Huber, Laura Flesch, Kathy Demmel, Adam Lane, Dean W. Beebe, Lori Crosby, John Hogenesch, David F. Smith, Stella Davies, Christopher E. Dandoy Tags: Brief Article Source Type: research

Trajectory of Sleep, Depression and Quality of Life in Pediatric HSCT Recipients
Adult hematopoietic stem cell transplant (HSCT) recipients and adult caregivers of pediatric HSCT recipients have poor sleep, due in part to nocturia, staff cares, and noise.1 –5 In these patients, the effects of prolonged sleep disruption during hospitalization have been shown to persist for months after discharge, negatively affecting sleep hygiene as well as quality of life.6–8 Adult HSCT patients have been shown to have sleep disturbances up to one-year post-trans plant, and these disturbances occur concurrently with depression and anxiety. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 3, 2024 Category: Hematology Authors: YunZu Michele Wang, John F. Huber, Laura Flesch, Kathy Demmel, Adam Lane, Dean W. Beebe, Lori Crosby, John Hogenesch, David F. Smith, Stella Davies, Christopher E. Dandoy Source Type: research

A More MAGICal Alogrithm in Acute GVHD
Acute Graft-versus-Host Disease (aGVHD) is an unpredictable and potentially life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT).1 Inroads have been made, identifying two biologically relevant markers of aGVHD: suppression of tumorigenicity 2 (ST2) and Regenerating islet-derived 3-alpha (Reg-3 α).2,3 ST2 is the soluble receptor of interleukin-33 that is released when gastrointestinal crypt is damaged.4 Reg-3α is a peptide with regenerative property released from damaged intestinal crypt in the event of GVHD. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2024 Category: Hematology Authors: Sanghee Hong, Stefanie Sarantopoulos Tags: The Bottom Line Source Type: research

Building a Transplant Center: From the Karolinska to Kathmandu
In the Icelandic language, the word von means hope, an uplifted spirit, persistence and enduring resilience. From the founding of bone marrow transplantation (BMT) by Don Thomas and other pioneers, this Nordic term has come to symbolize the journey of both transplant recipients and their physicians. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2024 Category: Hematology Authors: Olle Ringden, Damiano Rondelli Tags: Reflections Source Type: research

Picture Perfect Predictive Model: Does it Exist?
Editorial (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2024 Category: Hematology Authors: Chiranjeevi Sainatham, Tania Jain Tags: The Bottom Line Source Type: research

Masthead (Purpose and Scope)
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2024 Category: Hematology Source Type: research

Editorial Board
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2024 Category: Hematology Source Type: research

Officers and Directors of ASTCT
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2024 Category: Hematology Source Type: research

Table of Contents
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2024 Category: Hematology Source Type: research

Revised HLA-DP TCE-Core Permissiveness Model Better Defines Relapse Risk and Survival Following Haploidentical Transplant
Haploidentical donor transplantation (HIDT) utilizing post-transplant cyclophosphamide (PTCy) is an increasing utilized donor source worldwide for patients lacking fully matched related or unrelated donors.1,2 As most patients have more than one available potential haploidentical donor options, selection criteria are needed to optimize HIDT outcomes. Younger donor age appears to be the most consistent predictive variable for transplant outcome after PTCy-based HIDT.3-6 More recently, there has been greater appreciation regarding the protective effects of increased class II HLA disparity at the HLA-DR and HLA-DP loci on tra...
Source: Biology of Blood and Marrow Transplantation - March 30, 2024 Category: Hematology Authors: Scott R Solomon, Michael T Aubrey, Lizamarie Bachier-Rodriguez, Melhem M Solh, Katelin C Jackson, Xu Zhang, Christina L Roark, H. Kent Holland, Lawrence E. Morris, Asad Bashey Source Type: research

Returning to Work Following Hematopoietic Cell Transplantation: The Survivor's Perspective
The quality of survivorship after hematopoietic stem cell transplantation (HCT) is determined not only by cure of the disease for which the transplant was performed but also by the resumption of previous roles within the family, the community and the workplace.1 For many patients, return to work (RTW) serves as a metric of recovery from treatment and signifies the return to an identity beyond “patient,” and a positive step toward the future.1,2 HCT, which may be the only curative treatment for many patients with hematologic disorders, may result in failure to RTW and prolonged work limitations for treatment-related com...
Source: Biology of Blood and Marrow Transplantation - March 30, 2024 Category: Hematology Authors: Rachel B. Salit, Stephanie J. Lee, Neel S. Bhatt, Paul A. Carpenter, Xinyi Fan, Ailie Armstrong, Masumi Ueda Oshima, Laura Connelly-Smith, Elizabeth Krakow, Catherine J. Lee, Phuong Vo, Rohtesh Mehta, Karen L. Syrjala Source Type: research

Efficacy of autologous and allogeneic hematopoietic cell transplantation in adults with acute promyelocytic leukemia: results of a systematic review and meta-analysis
Acute promyelocytic leukemia (APL) represents a distinct subtype of acute myeloid leukemia, accounting for approximately 15% of cases in the United States1. Diagnosis of APL requires confirmation of the presence of a reciprocal translocation involving the promyelocytic leukemia (PML) gene on chromosome 15 and the retinoic acid receptor alpha (RARA) gene on chromosome 17 t(15;17), so called APL with PML::RARA fusion2, 3. Other variants of APL with different chromosomal aberrations have been described less frequently4-6. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 28, 2024 Category: Hematology Authors: Razan Mohty, Tea Reljic, Farah Yassine, Christian Kettaneh, Dua Al-Husni, Katelyn Keller, Talha Badar, Hemant Murthy, James Foran, Ambuj Kumar, Mohamed A. Kharfan-Dabaja Source Type: research

Immunosuppression-Free Status at 1 Year after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide
The success of allogeneic hematopoietic cell transplantation (HCT) is based on survival that is free of morbidity and mortality, allowing for a good quality of life for surviving patients. The long-term need for immunosuppression (IS) for control of chronic graft-versus-host disease (GVHD) has a significant impact on quality of life and is considered one of the main morbidities hindering the success of allogeneic HCT [1 –3]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 27, 2024 Category: Hematology Authors: Melhem Solh, Asad Bashey, Xu Zhang, H. Kent Holland, Lizamarie Bachier-Rdriguez, Lawrence E. Morris, Scott R. Solomon Tags: Full-Length Article Source Type: research

Immunosuppression-Free Status at One-year Post Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)
The success of allogeneic hematopoietic cell transplantation (HCT) is based on survival that is free of morbidity and mortality allowing for a good quality of life for surviving patients. Long term need of immunosuppression for control of chronic graft-versus-host disease (GVHD) has a significant impact on quality of life and is considered one of the main morbidities hindering the success of allogeneic transplantation.1-3 (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 27, 2024 Category: Hematology Authors: Melhem Solh, Asad Bashey, Xu Zhang, H Kent Holland, Lizamarie Bachier-Rdriguez, Lawrence E Morris, Scott R Solomon Source Type: research

A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
Allogeneic hematopoietic cell transplantation (HCT) cures large numbers of children with malignant and nonmalignant diseases but not all children who might benefit receive the procedure, despite advances in donor selection and supportive care [1 –3]. A major barrier to greater use of allogeneic HCT is the risk for developing acute graft-versus-host disease (GVHD), which occurs in about one third of children and causes substantial morbidity and mortality [4–7]. Advances in GVHD management are particularly important for children who under go transplant for nonmalignant diseases that are curable by allogeneic HCT and for ...
Source: Biology of Blood and Marrow Transplantation - March 26, 2024 Category: Hematology Authors: Muna Qayed, Urvi Kapoor, Scott Gillespie, Adrianna Westbrook, Paibel Aguayo-Hiraldo, Francis A. Ayuk, Mina Aziz, Janna Baez, Hannah Choe, Zachariah DeFilipp, Aaron Etra, Stephan A. Grupp, Elizabeth Hexner, Ernst Holler, William J. Hogan, Steven Kowalyk, P Tags: Pediatric Source Type: research